Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Lymphomas: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Lymphomas

Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)

Data Insights

ICG-122 by ICell Gene Therapeutics for T-Cell Leukemia: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Leukemia

Data Insights

ICG-122 by ICell Gene Therapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Cutaneous T-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Cutaneous T-Cell Lymphoma

Data Insights

ICG-122 by ICell Gene Therapeutics for Sezary Syndrome: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Sezary Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Sezary Syndrome

Data Insights

ICG-122 by ICell Gene Therapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

ICG-122 by ICell Gene Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

ICG-122 by ICell Gene Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

ICG-122 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According...

Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in Chronic Myelomonocytic Leukemia (CMML)